ScreenerHero

IMUX Immunic, Inc.

NAS · US · Healthcare · Biotechnology · imux.com
7.560USD-0.92%Mkt Cap: 103.15M $P/E: —

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap103.15M USD
Enterprise Value-47.83M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-97.17M USD
Revenue/Share—
Last Price7.560 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.22
PEG—
EV/EBITDA0.41
EV/Revenue—
P/S—
P/B0.84
EPS (TTM)-3.83
EPS (Forward)-2.43
52W Range
5.06020% of range17.43
52W High17.43 USD
52W Low5.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE1456.20%
ROA-404.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-85.81M USD
CapEx (TTM)161.00K USD
FCF Margin—
FCF Yield-49.84%
Net Debt-154.53M USD
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity-0.09
Current Ratio5.05
Quick Ratio4.97
Book Value/Sh9.35 USD
Cash/Share11.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateApr 15, 2019
Splits
Last Split1:10
Split DateApr 27, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)43.09 USD
Upside (mean)+470.0%
Target Range22.00 USD – 85.00 USD
22.00+470.0% to mean85.00
# Analysts11
Ownership
Shares Out.13.64M
Float12.01M
Insiders0.97%
Institutions71.18%
Short Interest
Short Ratio6.5d
Short % Float13.92%
Short % Out.13.15%
Shares Short1.79M
Short (prev mo.)1.28M
Technical
SMA 5013.08 (-42.2%)
SMA 20011.36 (-33.5%)
Beta1.45
S&P 52W Chg16.45%
Avg Vol (30d)387.74K
Avg Vol (10d)517.09K
Technical Indicators
RSI (14)21.4
MACD-1.5271
MACD Signal-1.4336
MACD Hist.-0.0935
BB Upper12.55 USD
BB Middle9.639 USD
BB Lower6.727 USD
BB Width60.43%
ATR (14)0.7804 USD
Vol Ratio (20d)1.20x